Calanusolie is een nieuwe, marine bron van omega-3-vetzuren. Deze olie is afkomstig van het zoöplankton Calanus finmarchicus dat in grote getalen voorkomt in de Noordelijke IJszee. Als voedingssupplement onderscheidt Calanusolie zich van visolie door een bredere werking. Naast de gunstige effecten van omega-3-vetzuren die bekend zijn van visolie, kan Calanusolie een meer uitgesproken effect hebben op de glucose-homeostase en op overgewicht. Dit maakt Calanusolie veelbelovend ter preventie van obesitas en diabetes type 2.
Beste bezoeker, u heeft geen toegang.
Enkel (web)abonnees hebben toegang tot tijdschriftartikelen. Het webabonnement is nog in de maak.
U kunt zich wel alvast (gratis) registreren en tal van andere webartikelen raadplegen!
Auteur
Trefwoorden:
Verschenen in
Referenties
Höper AC, Salma W, Khalid AM, et al. Oil from the marine zooplankton Calanus finmarchicus improves the cardiometabolic phenotype of diet-induced obese mice. Br J Nutr. 2013 Dec;110(12):2186-93.
Höper AC, Salma W, Sollie SJ, et al. Wax esters from the marine copepod Calanus finmarchicus reduce diet-induced obesity and obesity-related metabolic disorders in mice. J Nutr. 2014 Feb;144(2):164-9.
Calanus® Oil improves insulin sensitivity in elderly women – promising results of a newly finished intervention study. https://www.calanus.no/research-and-development/calanus-oil/calanus-oil-improves-insulin-sensitivity-in-elderly-women-promising-results-of-a-newly-finished-intervention-study.
ClinicalTrials.gov. Effect of Exercise and Omega-3 on Metabolic Health in Elderly (EXODYA). https://clinicaltrials.gov/ct2/show/study/NCT03386461?term=calanus+oil&rank=4.
Cook CM, Larsen TS, Derrig LD, et al. Wax Ester Rich Oil From The Marine Crustacean, Calanus finmarchicus, is a Bioavailable Source of EPA and DHA for Human Consumption. Lipids. 2016 Oct;51(10):1137-1144.
Application for the Approval of Calanus® Oil as an Ingredient for Use in Food Supplements, 2011.
Höper AC. Calanus oil and its lipid constituents. Impact on obesity and obesity-related metabolic disorders in rodents. Dissertation, The Arctic University of Norway, Tromsø, December 2013.
Ulven T, Christiansen E. Dietary Fatty Acids and Their Potential for Controlling Metabolic Diseases Through Activation of FFA4/GPR120. Annu Rev Nutr. 2015;35:239-63.
Christiansen E, Watterson KR, Stocker CJ, et al. Activity of dietary fatty acids on FFA1 and FFA4 and characterisation of pinolenic acid as a dual FFA1/FFA4 agonist with potential effect against metabolic diseases. Br J Nutr. 2015 Jun 14;113(11):1677-88.
Morishita M, Tanaka T, Shida T, et al. Usefulness of colon targeted DHA and EPA as novel diabetes medications that promote intrinsic GLP-1 secretion. J Control Release. 2008 Dec 8;132(2):99-104.
Schilperoort M, van Dam AD, Hoeke G, et al. The GPR120 agonist TUG-891 promotes metabolic health by stimulating mitochondrial respiration in brown fat. EMBO Mol Med. 2018 Mar;10(3).
